Metacrine (Metacrine) Float Percentage Of Total Shares Outstanding : 76.50% (As of May. 07, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Metacrine Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Metacrine's float shares is 33.53 Mil. Metacrine's total shares outstanding is 43.83 Mil. Metacrine's float percentage of total shares outstanding is 76.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Metacrine's Insider Ownership is 12.94%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Metacrine's Institutional Ownership is 0.03%.

Metacrine Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Metacrine's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	33.53	/	43.83
	=	76.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metacrine (Metacrine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metacrine Inc (OTCPK:MTCR) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3985 Sorrento Valley Boulevard, Suite C, San Diego, CA, USA, 92121

Website

https://www.metacrine.com

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Executives

Michael York	officer: Chief Business Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Preston Klassen	director, officer: President & CEO	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Hubert C Chen	officer: Chief Medical Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Julia C. Owens	director	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451